iCCA	Intrahepatic Cholangiocarcinoma
HCC	Hepatocellular Carcinoma
GemCis	Gemcitabine plus cisplatin
GEMOX	Gemcitabine and oxaliplatin
HAIC	Hepatic Arterial Infusion Chemotherapy
BTCs	Biliary Tract Cancers
TACE	Transarterial Chemoembolization
FOLFOX	Oxaliplatin, leucovorin plus 5-fluorouracil
ICIs	Immune Checkpoint Inhibitors
TKIs	Tyrosine Kinase Inhibitors
PD-1	Programmed Cell Death Protein-1
CT	Computed Tomography
MRI	Magnetic Resonance Imaging
RECIST	Response Evaluation Criteria in Solid Tumors
OS	Overall Survival
PFS	Progression-Free Survival
ORR	Objective Response Rate
DCR	Disease Control Rate
WES	Whole Exome Sequencing
IHC	Immunohistochemistry
HR	Hazard Ratio
CI	Confidence Interval
IQR	Interquartile Range
SD	Standard Deviation
TRAEs	Treatment-related Adverse Events
TMB	Tumor Mutation Burden
HRR	Homologous Recombination Repair
DDR	DNA Damage Response
TILs	Tumor-infiltrating Lymphocytes
TIME	Tumor Immune Microenvironment.